CR20190249A - Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcus - Google Patents
Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcusInfo
- Publication number
- CR20190249A CR20190249A CR20190249A CR20190249A CR20190249A CR 20190249 A CR20190249 A CR 20190249A CR 20190249 A CR20190249 A CR 20190249A CR 20190249 A CR20190249 A CR 20190249A CR 20190249 A CR20190249 A CR 20190249A
- Authority
- CR
- Costa Rica
- Prior art keywords
- polypeptide
- seq
- amino acid
- set forth
- nos
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un constructo de fusión de fórmula (I): X-A-ligante-B-Z (I) donde : (1) A y B son idénticos o diferentes y son independientemente: (a) un polipéptido que comprende un polipéptido SACOL0029 según lo expuesto en cualquiera de las secuencias descritas en FIG. 24 (SEC ID NOs: 5 y 121 a 131), un polipéptido SACOL0264 (SEC ID NO : 185), un polipéptido SACOL0442 según lo expuesto en cualquiera de las secuencias descritas en FIG. 22D (SEC ID NOs: 29 y 82 a 92), un polipéptido SACOL0718 (SEC ID NO : 186), un polipéptido SACOL0720 según lo expuesto en cualquiera de las secuencias descritas en FIGs. 23I-J (SEC ID NOs: 11 y 109 a 120), un polipéptido SACOL1353 (SEC ID NO : 187), un polipéptido SACOL1416 (SEC ID NO : 188), un polipéptido SACOL1611 (SEC ID NO : 189), un polipéptido SACOL1867 según lo expuesto en cualquiera de las secuencias descritas en FIG. 25D (SEC ID NOs: 152 a 164), un polipéptido SACOL1912 (SEC ID NO : 43), un polipéptido SACOL1944 (SEC ID NO : 190), un polipéptido SACOL2144 (SEC ID NO : 191), un polipéptido SACOL2365 (SEC ID NO : 192), un polipéptido SACOL2385 (SEC ID NO : 50) o un polipéptido SACOL2599 (SEC ID NO : 193), sobre la base de la nomenclatura genética del genoma COL (SACOL) de Staphylococcus aureus expuesto en la Secuencia de Referencia en el NCBI NC_002951.2; (b) un polipéptido codificado por un gen de un mismo operón que un gen que codifica al polipéptido de (a); (c) un polipéptido que comprende un fragmento inmunogénico de por lo menos 13 aminoácidos consecutivos de (a) o (b); (d) un polipéptido que comprende una secuencia de aminoácidos por lo menos 60% idéntica en su totalidad a la secuencia del polipéptido de cualquiera de (a) a (c); o (e) un polipéptido que comprende una variante inmunogénica que comprende por lo menos 13 aminoácidos consecutivos de cualquiera de (a) a (c); (2) el ligante es una secuencia de aminoácidos de por lo menos un aminoácido o está ausente; (3) X está ausente o es una secuencia de aminoácidos de por lo menos un aminoácido; y (4) Z está ausente o es una secuencia de aminoácidos de por lo menos un aminoácido. Se proporcionan además composiciones y kits que comprenden la fusión y usos de estas fusiones, composiciones y kits.There is provided a fusion construct of formula (I): X-A-linker-B-Z (I) wherein : (1) A and B are identical or different and are independently: (a) a polypeptide comprising a SACOL0029 polypeptide as set forth in any one of the sequences depicted in FIG. 24 (SEQ ID NOs: 5 and 121 to 131), a SACOL0264 polypeptide (SEQ ID NO : 185), a SACOL0442 polypeptide as set forth in any one of the sequences depicted in FIG. 22D (SEQ ID NOs: 29 and 82 to 92), a SACOL0718 polypeptide (SEQ ID NO : 186), a SACOL0720 polypeptide as set forth in any one of the sequences depicted in FIGs. 23I-J (SEQ ID NOs: 11 and 109 to 120), a SACOL1353 polypeptide (SEQ ID NO : 187), a SACOL1416 polypeptide (SEQ ID NO : 188), a SACOL1611 polypeptide (SEQ ID NO : 189), a SACOL1867 polypeptide as set forth in any one of the sequences depicted in FIG. 25D (SEQ ID NOs: 152 to 164), a SACOL1912 polypeptide (SEQ ID NO : 43), a SACOL1944 polypeptide (SEQ ID NO : 190), a SACOL2144 polypeptide (SEQ ID NO : 191), a SACOL2365 polypeptide (SEQ ID NO : 192), a SACOL2385 polypeptide (SEQ ID NO : 50) or a SACOL2599 polypeptide (SEQ ID NO : 193), based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome set forth in NCBI Reference Sequence NC_002951.2; (b) a polypeptide encoded by a gene from a same operon as a gene encoding the polypeptide of (a); (c) a polypeptide comprising an immunogenic fragment of at least 13 consecutive amino acids of (a) or (b); (d) a polypeptide comprising an amino acid sequence at least 60% identical overall to the sequence of the polypeptide of any one of (a) to (c); or (e) a polypeptide comprising an immunogenic variant comprising at least 13 consecutive amino acids of any one of (a) to (c); (2) the linker is an amino acid sequence of at least one amino acid or is absent; (3) X is absent or is an amino acid sequence of at least one amino acid; and (4) Z is absent or is an amino acid sequence of at least one amino acid. Also provided are compositions and kits comprising the fusion and uses of these fusions, compositions and kits.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411120P | 2016-10-21 | 2016-10-21 | |
| PCT/CA2017/051253 WO2018072031A1 (en) | 2016-10-21 | 2017-10-20 | Vaccine constructs and uses thereof against staphylococcus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190249A true CR20190249A (es) | 2019-10-16 |
Family
ID=62018642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190249A CR20190249A (es) | 2016-10-21 | 2017-10-20 | Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcus |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324815B2 (es) |
| EP (1) | EP3529260A4 (es) |
| JP (2) | JP7181208B2 (es) |
| KR (1) | KR20190082229A (es) |
| CN (1) | CN109843910A (es) |
| AR (1) | AR109847A1 (es) |
| AU (2) | AU2017346974B2 (es) |
| BR (1) | BR112019007796A2 (es) |
| CA (1) | CA3037070A1 (es) |
| CL (1) | CL2019001048A1 (es) |
| CO (1) | CO2019005169A2 (es) |
| CR (1) | CR20190249A (es) |
| DO (1) | DOP2019000102A (es) |
| IL (1) | IL265869A (es) |
| MX (2) | MX2019004539A (es) |
| MY (1) | MY195369A (es) |
| NZ (1) | NZ751880A (es) |
| PE (1) | PE20191320A1 (es) |
| PH (1) | PH12019500843A1 (es) |
| RU (2) | RU2766354C2 (es) |
| SG (2) | SG10201912431XA (es) |
| TW (1) | TW201819402A (es) |
| UY (1) | UY37448A (es) |
| WO (1) | WO2018072031A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220185852A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6380370B1 (en) | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| PL229487B1 (pl) | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego |
| CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
| RU2419628C2 (ru) | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Иммуногенная композиция для применения в вакцинации против стафилококков |
| AU2005333603A1 (en) * | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
| KR100729954B1 (ko) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법 |
| WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| BRPI1011856A2 (pt) | 2009-03-23 | 2020-11-03 | Epitopix, Llc | polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso |
| NZ612315A (en) * | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| PT2547361T (pt) | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações |
| MX340446B (es) | 2011-06-19 | 2016-07-08 | Univ New York | Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas. |
-
2017
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 AR ARP170102922A patent/AR109847A1/es unknown
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/ko active IP Right Grant
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/es unknown
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/ru active
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/ja active Active
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/es unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/zh active Pending
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 CR CR20190249A patent/CR20190249A/es unknown
- 2017-10-20 UY UY0001037448A patent/UY37448A/es unknown
- 2017-10-20 TW TW106136089A patent/TW201819402A/zh unknown
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/pt unknown
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/ru unknown
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/es unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/es unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/es unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/es unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en active Pending
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034981A5 (es) | ||
| PE20232039A1 (es) | Mutantes de proteina f de rsv | |
| ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| PE20220960A1 (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros | |
| CO2018006947A2 (es) | Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida | |
| AR083839A1 (es) | Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos | |
| ES2383716T3 (es) | Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| PE20131363A1 (es) | Composicion vacunal para el control de las infestaciones por ectoparasitos | |
| AR065282A1 (es) | Composiciones y metodos que utilizan arn de transferencia de genes tipo cad para el control de nematodos | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| CO2019010062A2 (es) | Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| PE20230343A1 (es) | Peptidos que estimulan respuestas inmunitarias antitumorales | |
| CR20190249A (es) | Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcus | |
| AR083766A1 (es) | Peptido inmunogenico | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
| JP2015129652A5 (es) | ||
| BR112022010228A2 (pt) | Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas | |
| CL2017002972A1 (es) | Péptido anti microbiano del tipo nk-lisina, para el control de agentes patógenos y su uso como adyuvante molecular. | |
| BR112018001542A2 (pt) | indutor da imunidade, polipeptídeo possuindo uma atividade indutora da imunidade, célula apresentadora de antígeno isolada e célula t isolada | |
| MX2015006599A (es) | Secuencias de ácidos desoxirribonucleicos sintéticos y proteinas recombinantes heterólogas de la hemaglutinina del virus influenza expresadas en cloroplasto de chlamydomonas reinhardtii y su uso en vacunas. | |
| AR102120A1 (es) | Interferón modificado con inmunogenicidad reducida |